Mahmoud M. Magdy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahmoud M. Magdy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amira Afifi
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication Anwar Albasri
Rheumatology Unit, Al‐Sabah Hospital, Shuwaikh Industrial, Kuwait
1 shared publicationAshraf A. Mostafa
Rheumatology Department, Faculty of Medicine, Al Azhar University, Damietta, Egypt
1 shared publication- Eman S Elgharabawy
Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication Faisal Alsaqabi
Rheumatology Unit, Al‐Sabah Hospital, Shuwaikh Industrial, Kuwait
1 shared publication- Mai M. Malek
Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication
Latest Publications
- Open Access
- 29 January 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (1)
Behçet’s disease: recurrent ischemic stroke as an initial presentation – a case based review
Behçet’s disease (BD) is a rare systemic vasculitis that is characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Although neurological involvement is a known complication, ischemic stroke remains uncommon. Herein, we report a 37-year-old Kuwaiti woman who experienced recurrent ischemic stroke with no traditional risk factors. Imaging studies, including magnetic resonance imaging and angiography, confirmed the diagnosis of recurrent ischemic stroke and identified the underlying vasculitic changes. A detailed examination revealed a history of recurrent orogenital ulcers, leading to a diagnosis of BD. High-dose corticosteroids, azathioprine, and antiplatelet treatment were effectively used to manage her acute strokes and underlying vasculitis, thus preventing further thrombotic events. Our case report underscores the difficulties of diagnosing BD with ischemic stroke as the initial manifestation and emphasizes the importance of a multidisciplinary approach that involves rheumatologists, neurologists, and radiologists to create an effective treatment plan. Our findings also underscore the need for medical practitioners to be more knowledgeable about ischemic stroke in young patients without risk factors from endemic areas of BD, and to develop effective therapy plans. Our review of the English literature indicates that this is only the fifth report of stroke as the first presentation of BD.
- 29 January 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (1)
Open AccessBehçet’s disease: recurrent ischemic stroke as an initial presentation – a case based review
Behçet’s disease (BD) is a rare systemic vasculitis that is characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Although neurological involvement is a known complication, ischemic stroke remains uncommon. Herein, we report a 37-year-old Kuwaiti woman who experienced recurrent ischemic stroke with no traditional risk factors. Imaging studies, including magnetic resonance imaging and angiography, confirmed the diagnosis of recurrent ischemic stroke and identified the underlying vasculitic changes. A detailed examination revealed a history of recurrent orogenital ulcers, leading to a diagnosis of BD. High-dose corticosteroids, azathioprine, and antiplatelet treatment were effectively used to manage her acute strokes and underlying vasculitis, thus preventing further thrombotic events. Our case report underscores the difficulties of diagnosing BD with ischemic stroke as the initial manifestation and emphasizes the importance of a multidisciplinary approach that involves rheumatologists, neurologists, and radiologists to create an effective treatment plan. Our findings also underscore the need for medical practitioners to be more knowledgeable about ischemic stroke in young patients without risk factors from endemic areas of BD, and to develop effective therapy plans. Our review of the English literature indicates that this is only the fifth report of stroke as the first presentation of BD.
- Open Access
- 31 December 2022
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 16 (12) , 1852-1859
Susceptibility of carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital, Egypt: A matter of hope
Introduction: Carbapenem-resistant Enterobacterales (CRE) are particularly worrisome pathogens because of their resistance to last-resort antibiotics, significant morbidity, and mortality. With limited treatment options, new therapeutic choices have become available for the management of CRE infections. Data regarding the efficacy of these novel agents are still limited particularly in a low-middle-income country like Egypt. This study aims to assess the prevalence of different carbapenemase genes among CRE isolates and the susceptibility of these isolates to novel antibiotics for improving antibiotic policy and infection control strategies in Egypt. Methodology: In this cross-sectional study, 260 Enterobacterales were recovered from patients admitted to intensive care units between January and June 2021. Susceptibility testing was conducted using Kirby-Bauer method. Molecular detection of five carbapenemase genes, namely blaKPC, blaIMP, blaVIM, blaNDM, blaOXA-48 was done using polymerase chain reaction (PCR). Results: Of the 260 Enterobacterales, 34.6% were found to be carbapenems resistant. All of the CRE isolates were multi-drug resistant exhibiting resistance to most antibiotics. All isolates harbored one or more carbapenemases genes. The most prevalent was blaNDM (84.4%), followed by blaOXA-48 (73.3%), blaKPC (13.3%), blaIMP (2.2%), while blaVIM gene wasn’t detected. Among 62.2% of the CRE isolates, two or more carbapenemase genes co-existed. For the new antibiotics tested, 100% of CRE resisted ceftolozane/tazobactam, 86.7% resisted ceftazidime/avibactam, 51.1% were resistant to eravacyclin, and 42.2% were resistant to cefiderocol. Conclusions: A high percentage of resistance to carbapenems among Enterobacterales isolates was revealed. blaNDM was found to be the most predominant carbapenemase gene. A high rate of CRE resistance to novel agents signifies a major threat.
- 31 December 2022
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 16 (12) , 1852-1859
Open AccessSusceptibility of carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital, Egypt: A matter of hope
Introduction: Carbapenem-resistant Enterobacterales (CRE) are particularly worrisome pathogens because of their resistance to last-resort antibiotics, significant morbidity, and mortality. With limited treatment options, new therapeutic choices have become available for the management of CRE infections. Data regarding the efficacy of these novel agents are still limited particularly in a low-middle-income country like Egypt. This study aims to assess the prevalence of different carbapenemase genes among CRE isolates and the susceptibility of these isolates to novel antibiotics for improving antibiotic policy and infection control strategies in Egypt. Methodology: In this cross-sectional study, 260 Enterobacterales were recovered from patients admitted to intensive care units between January and June 2021. Susceptibility testing was conducted using Kirby-Bauer method. Molecular detection of five carbapenemase genes, namely blaKPC, blaIMP, blaVIM, blaNDM, blaOXA-48 was done using polymerase chain reaction (PCR). Results: Of the 260 Enterobacterales, 34.6% were found to be carbapenems resistant. All of the CRE isolates were multi-drug resistant exhibiting resistance to most antibiotics. All isolates harbored one or more carbapenemases genes. The most prevalent was blaNDM (84.4%), followed by blaOXA-48 (73.3%), blaKPC (13.3%), blaIMP (2.2%), while blaVIM gene wasn’t detected. Among 62.2% of the CRE isolates, two or more carbapenemase genes co-existed. For the new antibiotics tested, 100% of CRE resisted ceftolozane/tazobactam, 86.7% resisted ceftazidime/avibactam, 51.1% were resistant to eravacyclin, and 42.2% were resistant to cefiderocol. Conclusions: A high percentage of resistance to carbapenems among Enterobacterales isolates was revealed. blaNDM was found to be the most predominant carbapenemase gene. A high rate of CRE resistance to novel agents signifies a major threat.